GlassScriptPhysician profile
Antonio E Sotomayor
NPI 1043321961
$10,063.20
in general payments reported to CMS, 2019-2025
58 companies · $1,951 in 2025
The $1,951 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,605 · 2020: $2,073 · 2021: $654 · 2022: $718 · 2023: $1,035 · 2024: $2,027 · 2025: $1,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,012.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,295.04 | 2021-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $952.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $789.53 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $778.64 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $708.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $508.75 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $434.11 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $355.44 | 2024-2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $336.25 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $281.04 | 2019-2024 | Nuplazid |
| Pfizer INC. | $280.61 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $230.20 | 2019-2022 | |
| Amgen INC. | $195.13 | 2019-2024 | Evenity, Prolia |
| Teva Pharmaceuticals USA, INC. | $174.42 | 2019-2023 | Austedo Xr |
| Tg Therapeutics, INC. | $167.36 | 2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Sotomayor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.